drugset / Trial / NCT01560949
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to learn if a chemotherapy combination called modified Folfirinox (or mFolfirinox), followed by a combination of gemcitabine and radiation therapy, followed by surgery, can help to control pancreatic cancer. The safety of this treatment will also be studied. mFolfirinox consists of 5-FU, oxaliplatin, and irinotecan. These 3 drugs, along with gemcitabine, are each designed to block the growth of cancer cells, which may lead to cancer cell death.
Timeline
- Start
- 2012-06-14
- Primary completion
- 2019-02-20
- Completion
- 2019-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 350 mg/m2 | Intravenous |
| Subject | Irinotecan | Small molecule | 150 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 75 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2000 mg/m2 | Intravenous |